The NAFLD burden on mortality and morbidities in general population: A community‐based longitudinal study ( NASH‐CO study)
Liver International · 2023
DOI: 10.1111/liv.15674 ↗Kurz gefasst
Fachartikel in der Zeitschrift Liver International, 2023. Verfasst von Oumarou Nabi und 8 weiteren Autor:innen. Beteiligte Einrichtung: Sorbonne University, Inserm, Pierre Louis Institute of Epidemiology and Public Health (IPLESP), AP-HP, Saint-Antoine Hospital, Paris, France. Hauptthemen laut MEDLINE: Non-alcoholic Fatty Liver Disease, Renal Insufficiency, Chronic, Cardiovascular Diseases. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 42 Literaturangaben.
Abstract (Originalsprache)
Background
The impact of non‐alcoholic fatty liver disease (NAFLD) on morbidity and mortality has yet to be documented at the general population level. This study aimed to assess whether NAFLD was associated with morbidities and mortality and to estimate its impact on health status and mortality.
Methods
The study population consisted of 137 206 participants from Constances cohort. Non‐invasive diagnosis of NAFLD and advanced fibrosis was performed using the fatty liver index and Forns index, respectively. Constances data were linked to health care and hospitalization data to identify liver‐related events, cardiovascular diseases (CVD), extrahepatic cancers (EHC), chronic kidney disease (CKD) and all‐cause mortality.
Results
The prevalence of NAFLD was 18.3% in subjects without other chronic liver diseases, among whom 2.7% had fibrosis. NAFLD after IPTW‐weighted remained associated with an increased risk of death (HR 1.26, 95% CI 1.01–1.57), hepatic‐related complications (HR 2.48, 95% CI 1.99–3.29), CVD (HR 1.42, 95% CI 1.30–1.55), EHC (HR 1.11, 95% CI 1.01–1.28) and CKD (HR 1.81, 95% CI 1.53–2.07) compared to those without chronic liver diseases risk factors (Non‐NAFLD). In the trend analysis over the study period of inclusion and compared to Non‐NAFLD, NAFLD has shown a fastest growing cause of hepatic events (HR 1.38, 95% CI 1.07–1.76 per year), CVD (HR 1.08, 95% CI 1.03–1.12), CKD (HR 1.16, 95% CI 1.07–1.25), and death (HR 1.39, 95% CI 1.39–1.50).
Conclusion
This large community‐based cohort showed that NAFLD was associated with excess morbidity and mortality and demonstrated a fastest‐growing trend.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Sorbonne University, Inserm, Pierre Louis Institute of Epidemiology and Public Health (IPLESP), AP-HP, Saint-Antoine Hospital, Paris, France.
- Division of General Medical Sciences, Department of Medicine, Washington University School of Medicine, Saint Louis, Missouri, USA.
- HepatoGastroenterology Department, Anger University Hospital, Angers, France.
- HIFIH Laboratory, UPRES EA3859, SFR 4208, Angers University, Angers, France.
- Hepatology Unit, Haut-Lévêque Hospital, Bordeaux University Hospital Branch, Bordeaux, France.
- Versailles-Saint Quentin University, UMS 11 Inserm, Versailles, France.
ORCID-Profile: Oumarou Nabi, Nathanaël Lapidus, Victor de Ledinghen, Lawrence Serfaty
Zitieren
APA
Nabi, O., Lapidus, N., Boursier, J., de Ledinghen, V., Kab, S., Renuy, A., Zins, M., Serfaty, L., & Lacombe, K. (2023). The NAFLD burden on mortality and morbidities in general population: A community‐based longitudinal study ( NASH‐CO study). Liver International. https://doi.org/10.1111/liv.15674
Vancouver
Nabi O, Lapidus N, Boursier J, de Ledinghen V, Kab S, Renuy A, et al. The NAFLD burden on mortality and morbidities in general population: A community‐based longitudinal study ( NASH‐CO study). Liver International. 2023. doi:10.1111/liv.15674
BibTeX
@article{Nabi2023,
author = {Nabi, Oumarou and Lapidus, Nathanaël and Boursier, Jerome and de Ledinghen, Victor and Kab, Sofiane and Renuy, Adeline and Zins, Marie and Serfaty, Lawrence and Lacombe, Karine},
title = {The NAFLD burden on mortality and morbidities in general population: A community‐based longitudinal study ( NASH‐CO study)},
journal = {Liver International},
year = {2023},
doi = {10.1111/liv.15674}
}
EUVIMED